1794760-31-8
1794760-31-8
Chemical Structure
Roflumilast-d4 N-Oxide
- CAS No.: 1794760-31-8
- Formula:C17H10D4Cl2F2N2O4
- Molecular Weight:423.23
IUPAC Name: 3,5-dichloro-4-(3-((cyclopropyl-2,2,3,3-d4)methoxy)-4-(difluoromethoxy)benzamido)pyridine 1-oxide
InChIKey: PCGSQNPMMSALEJ-LNLMKGTHSA-N
SMILES: [2H]C1([2H])C([2H])([2H])C1COC2=C(C=CC(C(NC3=C(Cl)C=[N+]([O-])C=C3Cl)=O)=C2)OC(F)F
Biological Activity: Roflumilast-d4 N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Roflumilast-d4 N-Oxide | 98.13% | Roflumilast-d4 N-Oxide is the deuterium labeled Roflumilast. Roflumilast is a selective PDE4 inhibitor with IC50s of 0.7, 0.9, 0.7, and 0.2 nM for PDE4A1, PDEA4, PDEB1, and PDEB2, respectively, without affecting PDE1, PDE2, PDE3 or PDE5 isoenzymes from various cells. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Roflumilast N-oxide (Standard) | 99.24% | Roflumilast N-oxide (Standard) is the analytical standard of Roflumilast N-oxide. This product is intended for research and analytical applications. Roflumilast N-oxide is a PDE type 4 inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Roflumilast N-oxide | 99.52% | Roflumilast N-oxide is a PDE type 4 inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
- [2]. Hatzelmann A, et al. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease. Pulm Pharmacol Ther. 2010 Aug;23(4):235-56. [Content Brief]
